Antidepressants spending: -34%
Antidepressants usage: +3%
Antipsychotics spending: +4%
Moving 40,000-plus people to a new brand of venlafaxine this year was challenging.
With this brand change, PHARMAC took the opportunity to provide additional education and support. We launched an online learning module aimed at health professionals, to help them communicate the change to their patients. So far, more than 600 health professionals (doctors, nurses, pharmacists) have accessed the module.
We also worked with Auckland University to study the venlafaxine brand change. 310 people participated in the study using an online questionnaire. The study looked at peoples’ preferences and perceptions, side effect reporting and perceived efficacy of the new brand.
The study also looked at the role of trust in pharmaceutical accompanies (suppliers). The results will help us better understand the brand change experience for people and inform our future approach in this type of situation.
A request for proposals (RFP) for the second-generation (atypical) antipsychotic medicine aripiprazole resulted in a new brand of the medicine being funded and removal of the Special Authority criteria, with savings of $4.2 million.
Aripiprazole is used for treating schizophrenia and bipolar disorder. The brand change to Aripiprazole Sandoz allows more people to access this treatment and means that aripiprazole can now be used as a first-line treatment option.
|Financial year||New antidepressants||Old antidepressants|
Last updated: 13 December 2018